Would violate 5th Amendment Takings Clause: Just look at

New Post Public Reply Private Reply Replies (0) Message Board
MarcS 10Blade #68857
815
Would violate 5th Amendment Takings Clause:
Quote:
Just look at what happened to 3M when they wanted to sell N-95 masks to other countries a few months ago.

There is a big difference between what 3M sells and what CytoDyn intends to sell.
3M has the legal right to sell their N-95 masks currently in the US.
CytoDyn has no legal right to sell leronlimab currently in the US.
As a result, if the US barred CytoDyn from selling outside the US without allowing CytoDyn to sell in the US or buying up CytoDyn's supply of leronlimab, it would violate the Fifth Amendment to the United States Constitution prohibition against Takings Without Just Compensation.
https://constitutioncenter.org/interactive-co...lauses/634
The US Government would need to immediately pay up "just compensation" for the supply of leronlimab. But, that would put the government, particularly the FDA in a bind. It would expose the FDA for failing to approve leronlimab.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Russel Metals Shows Strong Performance in Latest Earnings Report

Updated Category News Views 240

Russel Metals Inc. Reports Third Quarter Results for 2025 Russel Metals Inc. (TSX:RUS) has recently shared its financial performance for the three-month period ending September 30, 2025. The results reflect a positive trajectory in revenue and strategic initiatives to enhance its market position. Key Financial Metrics Overview In this quarter, Russel Metals has...

Continue Reading
KBC Group Shows Strong Capital Resilience Ahead of Changes

Updated Category News Views 257

KBC Group's Capital Position Remains Strong KBC Group has reported a robust standing in its capital levels, significantly exceeding the minimum capital requirements mandated by the European Central Bank (ECB). As part of the Supervisory Review and Evaluation Process (SREP) scheduled for the upcoming year, KBC received formal notification regarding its capital metrics....

Continue Reading
Synlogic's Q3 Financial Update Highlights Strategic Review

Updated Category News Views 79

Synlogic Provides Third Quarter 2024 Financial Results Synlogic, Inc. (NASDAQ: SYBX), a prominent biopharmaceutical firm dedicated to developing innovative therapeutics for serious diseases, has recently outlined its financial performance for the third quarter of 2024. The organization is actively working on advancing its mission to enhance healthcare through...

Continue Reading
Incannex Healthcare Sees Growth with Positive Fiscal Results

Updated Category News Views 98

Incannex Healthcare's Remarkable Financial Progress Incannex Healthcare Inc. (NASDAQ: IXHL) is making impressive strides in the biopharmaceutical world, focusing on breakthrough treatments for chronic diseases. Their recent fiscal year report outlines not only financial outcomes but also a plethora of operational and clinical advancements aimed at addressing significant...

Continue Reading
Revolutionizing Finance with ChatAnalyst at Alpha Liquid Terminal

Updated Category News Views 167

Alpha Liquid Terminal Introduces ChatAnalyst Financial Agent Recently, a game-changing tool was launched that promises to redefine how individuals manage and interpret financial data. This is powered by the innovative company, Alpha Liquid Terminal. The newly unveiled AI-driven financial analyst agent, known as ChatAnalyst, is designed to simplify and streamline financial...

Continue Reading